Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to pioneering and developing novel therapeutic agents to address significant unmet medical needs in viral diseases and liver diseases. The company's primary focus is on creating targeted therapies for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), and coronaviruses. Aligos leverages its expertise in virology, liver disease, and drug discovery to advance a portfolio of differentiated drug candidates designed to improve patient outcomes.
The headquarters serves as the central hub for Aligos' research and development, clinical operations, corporate strategy, and administrative functions. It's where key decisions are made, and scientific innovation is driven.
Located in a modern biotech park, the facility likely features state-of-the-art laboratory spaces and collaborative work environments conducive to scientific research. Specific architectural details are not publicly highlighted.
As a clinical-stage biopharmaceutical company, the work culture at Aligos HQ is likely dynamic, science-driven, and collaborative, with a strong emphasis on innovation, results, and addressing unmet medical needs. Employees are often highly skilled and passionate about drug development.
The South San Francisco location provides Aligos with access to a rich ecosystem of talent, research institutions, potential partners, and venture capital, crucial for a biopharmaceutical company's growth and success.
While headquartered in South San Francisco, USA, Aligos Therapeutics maintains a global outlook in its operations, particularly in clinical development. The company supports its research and clinical trials internationally, with a notable presence in Shanghai, China, to facilitate clinical development and operations in the Asia-Pacific region. This global approach allows Aligos to access diverse patient populations and collaborate with international research institutions and experts to advance its therapeutic pipeline for viral and liver diseases.
1 Corporate Drive, 2nd Floor
South San Francisco
CA
USA
Address: [Specific address not publicly available]
Facilitates engagement with regional clinical trial sites, investigators, and regulatory authorities, and supports the global development strategy by tapping into local expertise and patient populations.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Aligos Therapeutics' leadership includes:
Aligos Therapeutics has been backed by several prominent investors over the years, including:
In the past year, Aligos Therapeutics has seen key changes in its executive team, including the appointment of a new Chief Business Officer and the departure of its Chief Scientific Officer. These changes reflect the company's evolving strategic priorities as it advances its clinical programs.
Discover the tools Aligos Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Aligos Therapeutics primarily utilizes the email format combining the first initial of an employee's first name with their full last name, followed by '@aligos.com'. This is a common convention in many corporations, facilitating straightforward communication.
firstinitial + last@aligos.com
Format
lblatt@aligos.com
Example
85%
Success rate
Aligos Therapeutics / GlobeNewswire • May 9, 2024
Aligos Therapeutics announced its financial results for Q1 2024, highlighting progress in its CHB and MASH clinical programs, including ongoing Phase 1 studies for ALG-000184 and initiation of dosing for ALG-055009. The company also outlined its strategic priorities and upcoming milestones....more
Aligos Therapeutics / GlobeNewswire • April 2, 2024
Aligos announced the dosing of the first subject in its Phase 1 first-in-human clinical trial for ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH)....more
Aligos Therapeutics / GlobeNewswire • March 21, 2024
Aligos Therapeutics announced that Matthew W. McClure, M.D., Chief Scientific Officer, will be departing the company effective March 25, 2024. Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO, will assume Dr. McClure’s responsibilities on an interim basis....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Aligos Therapeutics, are just a search away.